AbbVie (ABBV) Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

15 analysts have issued 12-month price targets for AbbVie's shares. Their ABBV share price forecasts range from $140.00 to $195.00. On average, they predict the company's stock price to reach $165.79 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $161.61 at the beginning of the year. Since then, ABBV stock has decreased by 5.6% and is now trading at $152.64.
View the best growth stocks for 2023 here.

AbbVie saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 12,450,000 shares, a decline of 6.1% from the August 15th total of 13,260,000 shares. Based on an average daily trading volume, of 5,160,000 shares, the short-interest ratio is currently 2.4 days. Approximately 0.7% of the shares of the company are sold short.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ABBV earnings forecast.

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings data on Thursday, July, 27th. The company reported $2.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.79 by $0.12. The company earned $13.87 billion during the quarter, compared to analyst estimates of $13.52 billion. AbbVie had a net margin of 15.50% and a trailing twelve-month return on equity of 151.29%.

AbbVie declared a quarterly dividend on Friday, September 8th. Investors of record on Friday, October 13th will be given a dividend of $1.48 per share on Wednesday, November 15th. This represents a $5.92 annualized dividend and a yield of 3.88%. The ex-dividend date is Thursday, October 12th.
Read our dividend analysis for ABBV.

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), iShares Core High Dividend ETF (HDV), Invesco Pharmaceuticals ETF (PJP), Simplify Health Care ETF (PINK), Health Care Select Sector SPDR Fund (XLV) and VanEck Pharmaceutical ETF (PPH).

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.85%. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 121.81%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.57% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

AbbVie updated its third quarter 2023 earnings guidance on Friday, July, 28th. The company provided EPS guidance of $2.80-$2.90 for the period, compared to the consensus EPS estimate of $2.82. The company issued revenue guidance of $13.70 billion-$13.70 billion, compared to the consensus revenue estimate of $13.35 billion.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.88%), State Street Corp (4.43%), Capital International Investors (2.44%), Geode Capital Management LLC (1.98%), Capital Research Global Investors (1.84%) and Bank Julius Baer & Co. Ltd Zurich (1.59%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $152.64.

AbbVie (NYSE:ABBV) has a market capitalization of $269.42 billion and generates $58.05 billion in revenue each year. The company earns $11.84 billion in net income (profit) each year or $4.86 on an earnings per share basis.

The company employs 50,000 workers across the globe.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.